BCR and leukemia: We alsomade a vinylsulfonyl piperazine bearing derivative of the BCR-ABLand c-ABL kinase inhibitor dasatinib, ML 2–5, and demonstratedthe degradation of both the fusion oncogene and the parent kinasein K562 leukemia cancer cells (Figure S4b-S4d).